Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Adolescent (1)
- Adult (1)
- African Americans (1)
- Body height (1)
- Female (1)
-
- Gestational Age (1)
- Gestational age (1)
- Growth hormone (1)
- Growth hormone treatment (1)
- Health Status (1)
- Humans (1)
- Idiopathic short stature (1)
- Insurance Coverage (1)
- Intensive Care Units (1)
- Intensive Care Units, Neonatal (1)
- Isolated growth hormone deficiency (1)
- Maternal Age (1)
- Multiple pituitary hormone deficiency (1)
- Neonatal (1)
- Noonan Syndrome (1)
- Observational studies (1)
- Pregnancy (1)
- Pregnancy Outcome (1)
- Short stature (1)
- Social Class (1)
- Somatropin (1)
- Treatment outcome (1)
- Young Adult (1)
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
The Differential Effects Of Maternal Age, Race/Ethnicity And Insurance On Neonatal Intensive Care Unit Admission Rates., Beatriz E De Jongh, Robert Locke, David A Paul, Matthew Hoffman
The Differential Effects Of Maternal Age, Race/Ethnicity And Insurance On Neonatal Intensive Care Unit Admission Rates., Beatriz E De Jongh, Robert Locke, David A Paul, Matthew Hoffman
Department of Pediatrics Faculty Papers
BACKGROUND: Maternal race/ethnicity, age, and socioeconomic status (SES) are important factors determining birth outcome. Previous studies have demonstrated that, teenagers, and mothers with advanced maternal age (AMA), and Black/Non-Hispanic race/ethnicity can independently increase the risk for a poor pregnancy outcome. Similarly, public insurance has been associated with suboptimal health outcomes. The interaction and impact on the risk of a pregnancy resulting in a NICU admission has not been studied. Our aim was, to analyze the simultaneous interactions of teen/advanced maternal age (AMA), race/ethnicity and socioeconomic status on the odds of NICU admission.
METHODS: The Consortium of Safe Labor Database (subset …
Comparison Of Response To 2-Years' Growth Hormone Treatment In Children With Isolated Growth Hormone Deficiency, Born Small For Gestational Age, Idiopathic Short Stature, Or Multiple Pituitary Hormone Deficiency: Combined Results From Two Large Observational Studies., Peter A Lee, Lars Sävendahl, Isabelle Oliver, Maithé Tauber, Oliver Blankenstein, Judith Ross, Marta Snajderova, Viatcheslav Rakov, Birgitte Tønnes Pedersen, Henrik Thybo Christesen
Comparison Of Response To 2-Years' Growth Hormone Treatment In Children With Isolated Growth Hormone Deficiency, Born Small For Gestational Age, Idiopathic Short Stature, Or Multiple Pituitary Hormone Deficiency: Combined Results From Two Large Observational Studies., Peter A Lee, Lars Sävendahl, Isabelle Oliver, Maithé Tauber, Oliver Blankenstein, Judith Ross, Marta Snajderova, Viatcheslav Rakov, Birgitte Tønnes Pedersen, Henrik Thybo Christesen
Department of Pediatrics Faculty Papers
BACKGROUND: Few studies have compared the response to growth hormone (GH) treatment between indications such as isolated growth hormone deficiency (IGHD), born small for gestational age (SGA), idiopathic short stature (ISS), and multiple pituitary hormone deficiency (MPHD). The aim of this analysis of data, collected from two large ongoing observational outcome studies, was to evaluate growth and insulin-like growth factor-I (IGF-I) response data for children of short stature with IGHD, MPHD, SGA, or ISS following two years of treatment with the recombinant GH product Norditropin® (Novo Nordisk A/S, Bagsværd, Denmark).
METHODS: Analysis of auxologic data from two ongoing prospective observational …
Effect Of 4 Years Of Growth Hormone Therapy In Children With Noonan Syndrome In The American Norditropin Studies: Web-Enabled Research (Answer) Program® Registry., Peter A Lee, Judith Ross, John A Germak, Robert Gut
Effect Of 4 Years Of Growth Hormone Therapy In Children With Noonan Syndrome In The American Norditropin Studies: Web-Enabled Research (Answer) Program® Registry., Peter A Lee, Judith Ross, John A Germak, Robert Gut
Department of Pediatrics Faculty Papers
BACKGROUND: Noonan syndrome (NS) is a genetic disorder characterized by phenotypic features, including facial dysmorphology, cardiovascular anomalies, and short stature. Growth hormone (GH) has been approved by the United States Food and Drug Administration for short stature in children with NS. The objective of this analysis was to assess the height standard deviation score (HSDS) and change in HSDS (ΔHSDS) for up to 4 years (Y4) of GH therapy in children with NS.
METHODS: The American Norditropin Studies: Web-Enabled Research (ANSWER) Program®, a US-based registry, collects long-term efficacy and safety information on patients treated with Norditropin® (somatropin rDNA origin, Novo …